BioCentury | Nov 14, 2020
Management Tracks

Legend’s new look at the top; plus VC moves at Medicxi, OSI and Qiming

...years to found a start-up. During MacKinnon’s tenure, OSI...
...Biotech Corp. Oxford Sciences Innovation Medicxi Qiming Venture Partners USA Red Tree OSI...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...– Neuropilin 1RAB7A – RAB7A member RAS oncogene...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

AstraZeneca’s oncology R&D chief José Baselga sees the pharma’s push into ADCs as prologue for its quiet move into cell therapies, as the company builds up a stable of new modalities and targets...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Small molecule ERG, FLI1 inhibitor identified for retinopathy of prematurity

...of administration of the ERG and FLI1 inhibitor in mouse models.TARGET/MARKER/PATHWAY: v-ets erythroblastosis virus E26 oncogene...
...T. Griffin, Oklahoma Medical Research Foundation, Oklahoma City, Okla.email: courtney-griffin@omrf.org Claire Quang Oklahoma Medical Research Foundation v-ets erythroblastosis virus E26 oncogene...
BioCentury | Oct 27, 2020
Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

...STK11 as a potential biomarker, and help validate antitumor immunity as a component of the oncogene...
...sevenless homolog 1STK11 (LKB1 ) – Serine/threonine kinase 11 Lauren Martz sotorasib (AMG 510) MRTX849 Mirati Therapeutics Inc. Amgen Inc. KRAS proto-oncogene...
BioCentury | Oct 27, 2020
Distillery Therapeutics

PCF11 binding site on E3 ubiquitin ligase MAGEA11 identified as neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Interrupting the interaction between the oncogenic E3 ubiquitin ligase MAGEA11 and its substrate PCF11 could treat neuroendocrine tumors. Crystallographic analysis of the MAGEA11-PCF11 complex identified a shallow cleft on...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...proto-oncogene, GTPase MYC (c-Myc) – v-myc myelocytomatosis viral oncogene...
BioCentury | Sep 30, 2020
Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

...growth factor receptor APD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1RET - Ret proto-oncogene Paul...
BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

...peptide-1 receptorKRAS (K-Ras) Lauren Martz Carmot Therapeutics Inc. Amgen Inc. KRAS proto-oncogene...
BioCentury | Sep 29, 2020
Distillery Therapeutics

YAP1 activation to treat for colorectal cancer

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer Activating YAP1, a transcriptional activator of the often oncogenic Hippo pathway, could treat colorectal cancer. In patient-derived colorectal cancer organoids, expression of a constitutively active YAP1 mutant reduced growth....
Items per page:
1 - 10 of 3041
BioCentury | Nov 14, 2020
Management Tracks

Legend’s new look at the top; plus VC moves at Medicxi, OSI and Qiming

...years to found a start-up. During MacKinnon’s tenure, OSI...
...Biotech Corp. Oxford Sciences Innovation Medicxi Qiming Venture Partners USA Red Tree OSI...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...– Neuropilin 1RAB7A – RAB7A member RAS oncogene...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

AstraZeneca’s oncology R&D chief José Baselga sees the pharma’s push into ADCs as prologue for its quiet move into cell therapies, as the company builds up a stable of new modalities and targets...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Small molecule ERG, FLI1 inhibitor identified for retinopathy of prematurity

...of administration of the ERG and FLI1 inhibitor in mouse models.TARGET/MARKER/PATHWAY: v-ets erythroblastosis virus E26 oncogene...
...T. Griffin, Oklahoma Medical Research Foundation, Oklahoma City, Okla.email: courtney-griffin@omrf.org Claire Quang Oklahoma Medical Research Foundation v-ets erythroblastosis virus E26 oncogene...
BioCentury | Oct 27, 2020
Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

...STK11 as a potential biomarker, and help validate antitumor immunity as a component of the oncogene...
...sevenless homolog 1STK11 (LKB1 ) – Serine/threonine kinase 11 Lauren Martz sotorasib (AMG 510) MRTX849 Mirati Therapeutics Inc. Amgen Inc. KRAS proto-oncogene...
BioCentury | Oct 27, 2020
Distillery Therapeutics

PCF11 binding site on E3 ubiquitin ligase MAGEA11 identified as neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Interrupting the interaction between the oncogenic E3 ubiquitin ligase MAGEA11 and its substrate PCF11 could treat neuroendocrine tumors. Crystallographic analysis of the MAGEA11-PCF11 complex identified a shallow cleft on...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...proto-oncogene, GTPase MYC (c-Myc) – v-myc myelocytomatosis viral oncogene...
BioCentury | Sep 30, 2020
Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

...growth factor receptor APD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1RET - Ret proto-oncogene Paul...
BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

...peptide-1 receptorKRAS (K-Ras) Lauren Martz Carmot Therapeutics Inc. Amgen Inc. KRAS proto-oncogene...
BioCentury | Sep 29, 2020
Distillery Therapeutics

YAP1 activation to treat for colorectal cancer

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer Activating YAP1, a transcriptional activator of the often oncogenic Hippo pathway, could treat colorectal cancer. In patient-derived colorectal cancer organoids, expression of a constitutively active YAP1 mutant reduced growth....
Items per page:
1 - 10 of 3041